Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

Cancer

Volumn 109, Issue 10, 2007, Pages 2068-2076

  Ottmann, Oliver G ^a,f   Wassmann, Barbara ^a   Pfeifer, Heike ^a   Giagounidis, Aristoteles ^b   Stelljes, Matthias ^c   Dührsen, Ulrich ^d   Schmalzing, Marc ^e   Wunderle, Lydia ^a   Binckebanck, Anja ^a   Hoelzer, Dieter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ST JOHANNES HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

Acute lymphoblastic leukemia; BCR ABL; Minimal residual disease; Philadelphia chromosome; Randomised trial

Indexed keywords

BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ERUPTION; EDEMA; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HERPES ZOSTER; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; MALE; MENINGOENCEPHALITIS; MITRAL VALVE DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUROLOGIC DISEASE; PHILADELPHIA 1 CHROMOSOME; PNEUMONIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; STOMATITIS; SUBDURAL HEMATOMA; VIRUS MENINGITIS;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GENES, ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; SURVIVAL RATE;

EID: 34248575091     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22631     Document Type: Article

References (35)

1. Delannoy A, Ferrant A, Bosly A, et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol. 1990;45:90-93.
2. Virgilio JF, Moscinski LC, Ballester OF, et al. Acute lymphocytic leukemia (ALL) in elderly patients. Hematol Oncol. 1993;11:121-126.
3. Preti HA, O'Brien S, Giralt S, et al. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med. 1994;97:60-65.
4. Taylor PR, Reid MM, Bown N, et al. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood. 1992;80:1813-1817.
5. Ferrari A, Annino L, Crescenzi S, et al. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia. 1995;9:1643-1647.
6. Goekbuget N, de Witk M, Gerhardt A, et al. Results of a shortened, dose reduced treatment protocol in elderly patient with acute lymphoblastic leukemia [abstract]. Blood. 2000;96:3104a.
7. Annino L, Goekbuget N, Delannoy A. Acute lymphoblastic leukemia in the elderly. Hematol J. 2002;3:219-223.
8. Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006;43:126-133.
9. Legrand O, Marie JP, Marjanovic Z, et al. Prognostic factors in elderly acute lymphoblastic leukaemia. Br J Haematol. 1997;97:596-602.
10. Larson RA, Stock W, Hoezler D, et al. Acute lymphoblastic leukemia in adults. Hematology. Washington, DC: American Society of Hematology; 1999:547-561.
11. Hoelzer D, Goekbuget N. Treatment of elderly patients with acute lymphoblastic leukemia. ASCO Education Book, 41st Annual Meeting. May 13-17, 2005:533-539.
12. Gleissner B, Goekbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536-1543.
13. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
14. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:21-36.
15. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-1971.
16. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2004;344:1038-1042.
17. Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib mesylate (Glivec). Blood. 2004;103:1495-1498.
18. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-4407.
19. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-466.
20. Ribera JM, Oriol A, Gonzalez M, et al. Treatment of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) with concurrent chemotherapy and imatinib mesylate. Blood. 2004;104. Abstract 4483.
21. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the GRAAPH-2003 study. Blood. 2007;109:1408-1413.
22. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of Imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood. 2006;108:1469-1477.
23. Wassmann B, Goekbuget N, Scheuring UJ, et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol. 2003;82:716-720.
24. Cheson BD, Bennett JM, Kopecky KJ, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.
25. Scheming UJ, Pfeifer H, Wassmann B et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia. 2003;17:1700-1706.
26. Scheuring UJ, Pfeifer H, Wassmann B, et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl- positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood. 2003;101:85-90.
27. Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006;20:1526-1532.
28. Pfeifer H, Wassmann B, Pavlova A, et al. Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) developing resistance to imatinib Blood. 2005;106. Abstract 147.
29. Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002;99:1860-1862.
30. von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359:487-491.
31. Hofmann WK, Komor M, Wassmann B, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003;102:659-661.
32. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.
33. Kantarjian H, Giles F, Wunderle L, et al. AMN107, a novel, highly active, selective Bcr-Abl tyrosine kinase inhibitor in patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) who are resistant to imatinib mesylate therapy. N Engl J Med. 2006;354:2542-2551.
34. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
35. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.